Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408574 · ClinicalTrials.gov registry record · Phase 1
The Nicotinic Cholinergic System and Cognitive Aging
A Phase 1 study of Healthy Aging, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT03408574: Completed Phase 1 study of Healthy Aging, sponsored by University of Vermont.
NCT03408574 is a Phase 1 study of Healthy Aging that has completed, run by University of Vermont. The registered enrollment target is 104 participants, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03408574, a Phase 1 study of Healthy Aging, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a subset of receptors called the nicotinic system plays in cognition in healthy non-demented older adults (referred to as normal cognitive aging). This is critical because the ever growing healthy aging population will show declines in cognition that fall short of dementia but still impact functional abilities and independence. Maintaining good nicotinic system functioning throughout adulthood may lessen the cognitive symptoms of aging. At this time, it is not clear what the biological cause of age-related changes in cognition is. This study will examine the role of the nicotinic system in the healthy aging brain and examine its role in memory and thinking processes in older and younger adults.
Primary Outcome
Examine the effects of nicotinic blockade compared to placebo on the relationship between working memory performance and brain activation using fMRI BOLD signal in older and younger adults.
Conditions Studied
Interventions
- DRUG Nicotine patch, oral mecamylamine, placebo
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 1 |
What the finished NCT03408574 record still lists
NCT03408574 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 1 intervention - of which Nicotine patch, oral mecamylamine, placebo is the first listed.
NCT03408574 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT03408574 about?
NCT03408574 is a clinical study titled "The Nicotinic Cholinergic System and Cognitive Aging". Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a s...
What is the current status of trial NCT03408574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2016-10-01. Estimated completion is 2022-01-31.
What conditions does trial NCT03408574 study?
This clinical trial studies the following conditions: Healthy Aging.
What interventions are being tested in trial NCT03408574?
The interventions under investigation include: Nicotine patch, oral mecamylamine, placebo (DRUG).
Who is sponsoring clinical trial NCT03408574?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03408574 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03408574's enrollment target sits among peer trials
104 15th of 40 higher than 26 of 40 other Healthy Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
RECRUITING · NA
-
The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots
RECRUITING · NA
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
RECRUITING · NA
-
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
RECRUITING · NA
-
iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI